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Many asbestos-exposed subjects have minor parenchymal changes on high resolution computed
tomography (HRCT) that do not fulfil the diagnostic criteria for pulmonary fibrosis and asbes-
tosis. We investigated if these borderline parenchymal changes in asbestos-exposed subjects
are related to pulmonary inflammatory activity.
Exhaled nitric oxide was measured, exhaled breath condensate collected and HRCT scanned
in 104 subjects with moderate to high occupational asbestos exposure. Forty-one healthy
unexposed subjects served as a comparison group.
After excluding other pulmonary diseases, 35 asbestos-exposed subjects had normal paren-
chymal findings and 31 subjects had borderline parenchymal changes on HRCT. Lung function
was poorer in the latter group, but there was no difference in the degree of asbestos exposure
between these groups. As compared with the unexposed comparison group, asbestos-exposed
subjects with borderline parenchymal changes had increased alveolar NO concentration
(3.0  0.2 vs. 2.3  0.1 ppb, p Z 0.008) and increased levels of leukotriene B4 (12.2  1.1
vs. 3.3  0.8 pg/ml, p < 0.001) and 8-isoprostane (9.4  0.7 vs. 7.3  0.6 pg/ml,
pZ 0.021) in breath condensate. Asbestos-exposed subjects with normal parenchymal findings
had only increased breath condensate levels of leukotriene B4 (11.4  0.9, p < 0.001).nt of Pharmacology, Medical School, FIN-33014, University of Tampere, Tampere, Finland. Tel.: þ358
a.fi (L. Lehtima¨ki).
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Pulmonary inflammation and asbestos exposure 1043Borderline parenchymal changes on HRCT in asbestos-exposed subjects are associated with
increased markers of pulmonary inflammation. Such borderline parenchymal changes are likely
a mild or early form of the same pathological process that leads to asbestosis.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Inhalation of asbestos fibres causes an inflammatory
response in the lungs,1 that can lead to diffuse pulmonary
fibrosis called asbestosis. Development of asbestosis
requires moderate or heavy exposure to asbestos and takes
at least 15e20 years to develop in most cases. The diagnosis
of asbestosis is based on findings of diffuse interstitial
fibrosis when a history of sufficient exposure to asbestos
exists and other causes of pulmonary fibrosis have been
ruled out.2 Diagnostic criteria for diffuse pulmonary fibrosis
in asbestos-exposed subjects are currently based on find-
ings on chest X-ray. High resolution computed tomography
(HRCT) of the lungs is more sensitive than chest X-ray in the
diagnosis of pulmonary fibrosis among asbestos-exposed
subjects.3,4 Classification systems for HRCT changes have
been published,3e6 but there are no international
consensus criteria for the use of HRCT in diagnosing
asbestosis. Usually only marked diffuse fibrotic changes on
HRCT have been considered sufficient for the diagnosis of
asbestosis.4,5,7 However, only a minority of asbestos-
exposed subjects develop diffuse pulmonary fibrosis,
while most of the subjects show either normal HRCT or only
borderline parenchymal changes that do not fulfil the
diagnostic criteria for asbestosis.4,5 The significance of
borderline parenchymal changes and their relation to
pulmonary inflammatory activity are not known. It might be
that they represent an early stage of the disease process
with active inflammation that later on leads to diffuse
fibrosis and asbestosis.
Exhaled nitric oxide (NO) measurements and inflamma-
tory markers in exhaled breath condensate have recently
been introduced as non-invasive methods for assessing lung
inflammation.8 Measurement of exhaled NO at multiple
exhalation flow rates allows assessment of peripheral and
central NO output separately. The multiple flow rate
method is based on a mathematical model which divides
the lung into two compartments, namely the alveolar/
peripheral and bronchial/central compartments.9 While
alveolar air travels through bronchial tree during exhala-
tion, more NO diffuses from bronchial mucosa to luminal
air. By measuring exhaled NO at multiple flow rates, alve-
olar and bronchial NO output can be separately calculated.
The multiple exhalation flow rate method has been shown
to differentiate successfully between bronchial and alve-
olar inflammation in e.g. asthma, COPD and different forms
of alveolitis.10e13 Markers of pulmonary inflammation can
be non-invasively sampled by collecting exhaled breath
condensate (EBC). Leukotriene B4 (LTB4) is a potent
chemotactic factor for neutrophils,14 and has been used as
a marker for neutrophilic airway inflammation. 8-iso-
prostane is produced by lipid peroxidation and can be used
as a marker of oxidative injury in many diseases.15 Raised
levels of these mediators have been found in manyinflammatory lung diseases.8 Levels of myeloperoxidase
(MPO, a marker of neutrophilic activity) or interleukin-6 (IL-
6, a pro-inflammatory cytokine) can be measured in venous
blood to assess systemic inflammatory effects in respiratory
diseases.
In a previous study we have shown that asbestos-
exposed subjects with diffuse pulmonary fibrosis (i.e.
asbestosis) have increased alveolar NO output and high
levels of LTB4 and 8-isoprostane in exhaled breath
condensate reflecting the chronic pulmonary inflammation
and tissue damage.16 The aim of the present study was to
find out if borderline parenchymal changes on HRCT in
subjects with moderate to heavy asbestos exposure are
related to the degree of pulmonary inflammation.
Methods
Subjects
We recruited at the Clinic of Occupational Medicine at
Tampere University Hospital 104 men with moderate or
heavy occupational exposure to asbestos. To exclude other
pulmonary diseases that might affect the inflammatory
markers, the exclusion criteria were FEV1/FVC < 0.70,
bronchiectasis or any signs of emphysema on HRCT, diag-
nosed asthma, or asthma medication. Forty-one healthy
men with normal spirometry, no respiratory symptoms and
no notable exposure to asbestos or other harmful agents
served as an unexposed comparison group. All the subjects
were never-smokers or had quit smoking for at least 5 years
prior. The protocol was approved by the local ethics
committee and all the subjects gave their written informed
consent.
Study design
Spirometry17 and exhaled NO levels weremeasured, exhaled
breath condensate was collected, and venous blood sample
was drawn in all subjects. The subjects completed a ques-
tionnaire covering general health status, respiratory symp-
toms, smoking, and occupational history. The asbestos
exposure was estimated in fiber years (Zexposure time
[years]  exposure level [fibers/ml of air]) for each exposed
subject by experienced occupational physicians (PO and JU)
and a numerical asbestos exposure index was calculated.18
Subjects in the exposed groups had moderate or heavy
asbestos exposure (estimation of at least 20 fiber years)
considered sufficient to cause asbestosis. In the asbestos-
exposed subjects only, HRCT of the lungs was taken and
pulmonary diffusing capacity wasmeasured.19 The asbestos-
exposed subjects were divided into three groups based on
parenchymal findings on HRCT: (1) normal parenchymal
findings, (2) borderline parenchymal finding with minor
Table 1 Criteria for parenchymal fibrosis and the classi-
fication system of fibrosis severity on high resolution
computed tomography of the lungs. Modified from Huusko-
nen et al.5
Criteria for parenchymal
fibrosis
Septal thickening
Subpleural lines
Parenchymal bands
Honeycombing
Fibrosis classes
Class 0, normal
parenchymal finding
Normal finding by
all the criteria
Class I, borderline
parenchymal changes
1e2 criteria sporadically
in the lung periphery;
no honeycombing
Class II, mild fibrosis At least 2 criteria on both
sides and on several slices
in the lung periphery;
no honeycombing
Class III, moderate
fibrosis
Several criteria, changes
extend deeper into the lung
than in class 2; honeycombing
as a general rule
Class IV, severe fibrosis Several criteria or associated
findings extending deep into
the lung; honeycombing;
lung architectural change
Class V, extreme fibrosis Extremely severe and various
fibrotic changes; little normally
aerated lung left
1044 L. Lehtima¨ki et al.sporadic changes only, or (3) mild to extreme pulmonary
fibrosis (i.e. asbestosis). As the current study focused on the
borderline parenchymal changes, subjects with asbestosis
(group 3) were excluded from the analysis. Inflammatory
markers in exhaled air, breath condensate and serum were
compared between the unexposed comparison group,
asbestos-exposed subjects with normal parenchymal find-
ings, and those with borderline parenchymal changes.
Of the 104 asbestos-exposed men recruited, 33 were
excluded based on the above mentioned exclusion criteria.
Thirty-five subjects had normal parenchymal findings on
HRCT (fibrosis class 0), 31 subjects had borderline paren-
chymal changes (fibrosis classes 0.5e1.5), and 5 subjects
had pulmonary fibrosis (fibrosis classes  2.0) regarded as
asbestosis (Fig. 1).
HRCT grading
HRCT was scanned (Siemens Somatom Plus 4; Siemens
Medical, Erlangen, Germany) with 1 mm slices taken at
3 cm intervals using imaging parameters of 130e140 kV and
100e111 mA. The HRCT images were scored using
consensus reading by two experienced thoracic radiologists
(RJ and TV) blinded to the medical information of the
patients. Pulmonary fibrosis, emphysema, parietal pleural
plaques, and pulmonary nodules were scored separately as
described previously.3,5
The semiquantitative scoring of the HRCT findings indi-
cating interstitial lung fibrosis (septal thickening, sub-
pleural lines, parenchymal bands or honeycombing) in both
lungs was made according to a scale of classes from 0 to 5.
Fibrosis class 0 represents normal parenchymal finding,
class 1 represents borderline parenchymal finding with
minor sporadic changes only, and classes 2e5 represent
mild to severe diffuse pulmonary fibrosis (Table 1).5 If the
readers could not match the findings exactly with any given
fibrosis class, five subclasses (0.5, 1.5, 2.5, 3.5, 4.5) were
used. The fibrosis class 2 has been considered as a threshold
for the diagnosis of asbestosis.5
Exhaled NO measurement
Exhaled NO was measured with a Sievers NOA 280 analyser
(Sievers Instruments, Boulder, Colorado, USA) at four
exhalation flow rates of 50, 100, 200 and 300 ml/s without
nose clips. The desired exhalation flow rates were achieved
by letting the patients exhale through a mass flow meterFigure 1 Flow-chart of the asbestos-exconnected to a computer-controlled adjustable flow
restrictor.16 Three valid (flow rate within  2 ml/s from the
target flow) NO measurements at each flow rate were
collected. Alveolar NO concentration and bronchial NO flux
were calculated according to Tsoukias and George as
previously described by using exhalation flow rates of 100,
200 and 300 ml/s.9,10 In short, NO output (Zexhaled NO
concentration  flow rate) was plotted against flow rate,
and a linear regression was set. The slope and intercept of
the regression line are approximates of alveolar NO
concentration and bronchial NO flux, respectively. Except
for one subject who was excluded from the analysis due to
problems with NO measurement, linearity between NO
output and flow rate at range 100e300 ml/s was good
(r  0.97).posed subjects in the present study.
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Exhaled breath condensate was collected during 15 min of
tidal breathing with Ecoscreen condenser (Ecoscreen,
Jaeger, Hoechberg, Germany) while wearing nose clips. The
samples were stored at 70 C until assayed. LTB4 and
8-isoprostane concentrations in the condensates were
measured by immunoassay with a detection limit of 2 pg/ml
(Cayman Chemical Company, Ann Arbor, Michigan, USA).
The coefficients of variation were 5.7% for 8-isoprostane
and 6.0% for LTB4.
Serum samples
Venous blood was drawn as previously described.16 Serum
levels of myeloperoxidase (MPO) were measured by immu-
noassay with a detection limit of 0.2 pg/ml (HyCult
Biotechnology, Uden, The Netherlands); and the concen-
tration of interleukin-6 (IL-6) was determined by enzyme
immunoassay with a detection limit of 0.3 pg/ml (PeliPair
ELISA, Sanquin, Amsterdam, the Netherlands). The coeffi-
cients of variation were 8.7% for MPO and 6.1% for IL-6.
Statistical analysis
All the inflammatory parameters were normally distributed
(KolmogoroveSmirnov test). Analysis of variance with LSD
post-test or t-test were used to compare variables between
all the three groups or between the two asbestos-exposed
groups, respectively. Chi2-test was used for binary vari-
ables. Pearson’s r was used to test for correlations between
different inflammatory variables and lung function indices.Table 2 Subject characteristics.
Asbestos-exposed sub
Normal parenchymal
findings
N 35
Age (years) 62  1
Ex-smokers/never-smokers 25/10a
Pack-years among ex-smokers 15  2
Asbestos exposure (years) 35  2
Exposure: moderate/heavy 6/29
Exposure index 81  9
FVC below normal, n (%) 8 (23%)
TLCO below normal, n (%) 0 (0%)
FVC (% predicted) 92  3a
FEV1 (% predicted) 92  2a
TLCO (% predicted) 109  2
TLCO/VA (% predicted) 109  3
Pleural calcifications on HRCT, n (%) 24 (69%)
Extent of pleural plaques (cm2) 286  24
FVC, forced vital capacity.
FEV1, forced expiratory volume in 1 s.
TLCO, carbon monoxide transfer factor adjusted for haemoglobin.
TLCO/VA, specific carbon monoxide transfer factor adjusted for haem
HRCT, high resolution computed tomography.
a p < 0.05 as compared with the unexposed comparison group.
b p < 0.05 as compared with asbestos-exposed subjects with normaThe results are presented as mean  SEM. A p-value < 0.05
was considered as statistically significant. SPSS 12.0.1
software (SPSS Inc., Chicago, Illinois, USA) was used for
statistical analysis. Based on the SDs in different inflam-
matory markers in our previous studies, the current study
was calculated to have a power of 90% to detect a differ-
ence of z0.5 ppb in alveolar NO concentration and
differences ofz3.0 pg/ml andz4.5 pg/ml in EBC levels of
8-isoprostane and LTB4, respectively.
Results
Subject characteristics for the three groups are presented
in Table 2. Asbestos-exposed subjects with borderline
parenchymal changes were on average slightly older than
subjects in the other two groups. However, age was not
correlated with any of the inflammatory markers in exhaled
breath in any of the three groups. The proportion of
ex-smokers was lower in the unexposed comparison group
than in the asbestos-exposed subjects. There were no
differences in asbestos exposure between the subjects with
normal or borderline parenchymal findings on HRCT, but on
average, subjects with borderline parenchymal changes on
HRCT had poorer lung function and more extensive pleural
plaques than subjects with normal parenchymal findings.
The asbestos exposure index did not correlate with the
levels of any inflammatory markers in exhaled breath or
serum, or with the degree of parenchymal or pleural
changes on HRCT scans.
Alveolar NO concentration was increased in asbestos-
exposed subjects with borderline parenchymal changes on
HRCT (3.0  0.2 ppb) as compared with the unexposedjects Unexposed comparison
groupBorderline parenchymal
changes
31 41
67  1a,b 63  1
19/12a 15/26
19  5 11  2
35  2 e
6/25 e
78  9 e
10 (32%) 0 (0%)
6 (19%)a e
85  3a,b 103  2
85  3a,b 100  2
98  3b e
105  3 e
29 (94%)b e
362  22b e
oglobin.
l parenchymal findings.
1046 L. Lehtima¨ki et al.comparison group (2.3  0.1 ppb, p Z 0.009) or asbestos-
exposed subjects with normal parenchymal findings
(2.2  0.2 ppb, pZ 0.004). Asbestos-exposed subjects with
normal parenchymal findings had a slightly lower bronchial
NO flux (0.7  0.1 nl/s, p Z 0.033) as compared with the
unexposed comparison group (1.0  0.1 nl/s), whereas
subjects with borderline parenchymal changes (0.8  0.1 nl/
s, pZ 0.142) did not differ significantly from the comparison
group (Fig. 2). Exhaled NO concentration at low flow rates
reflects mainly bronchial NO output, and, accordingly,
exhaled NO concentrations at flow rates of 50 and 100 ml/s
were lower in asbestos-exposed subjects with normal
parenchymal findings than in the unexposed comparison
group. Subjects with borderline parenchymal changes were
not different from the comparison group at any flow rate
(Table 3).
8-isoprostane levels in exhaled breath condensate were
increased in asbestos-exposed subjects with borderline
parenchymal changes but not in subjects with normal
parenchymal findings, as compared with unexposed
subjects (Fig. 3). Condensate levels of LTB4 were increased
both in asbestos-exposed subjects with borderline and
normal parenchymal findings (Fig. 3, Table 3). Serum levels
of IL-6 and MPO were increased only in asbestos-exposed
subjects with borderline parenchymal changes (Table 3).
In the unexposed comparison group, bronchial NO flux
was lower in ex-smokers than in never-smokers (0.8  0.1
vs. 1.1  0.1 nl/s, p Z 0.019), but alveolar NO concen-
tration or markers in EBC were not significantly different
between ex-smokers and never-smokers. Among the
asbestos-exposed subjects, there were no differences in
any of the inflammatory markers in exhaled breath
between ex-smokers and never-smokers.
In asbestos-exposed subjects, alveolar NO concentration
correlated positively with 8-isoprostane and negatively
with LTB4 levels in exhaled breath condensate (Fig. 4).
Extent of pleural plaques on HRCT correlated positively
with serum levels of IL-6 (r Z 0.282, p Z 0.024) and
condensate levels of 8-isoprostane (rZ 0.254, pZ 0.043).
There were no other significant correlations between
inflammatory markers and indices of lung function either.Figure 2 Bronchial NO flux and alveolar NO concentration in asb
(BL, n Z 31) parenchymal findings on HRCT, and in the unexposedThe correlations between different markers were similar if
analysed separately in the subgroups of subjects with
normal or borderline parenchymal findings on HRCT.Discussion
In the present study, almost half of the subjects with
moderate to heavy asbestos exposure had borderline
parenchymal findings with minor sporadic changes on HRCT
not fulfilling the diagnostic criteria for asbestosis. These
subjects had also more extensive pleural plaques and poorer
lung function than those with normal parenchymal findings,
although there was no difference in the degree of asbestos
exposure. Subjects with borderline parenchymal changes
had increased alveolar NO concentration, increased levels of
LTB4 and 8-isoprostane in breath condensate, and increased
levels of IL-6 and MPO in serum, while only condensate levels
of LTB4 were increased in asbestos-exposed subjects with
normal parenchymal findings.
One previous study reports increased exhaled NO
concentration measured at a single flow rate in subjects
with asbestosis or pleural plaques.20 We have recently
demonstrated that the increased NO output in asbestosis is
peripheral in origin, which is in line with the parenchymal
inflammation and fibrosis in these subjects.16 In the present
study, alveolar NO concentration was normal in asbestos-
exposed subjects with normal parenchymal findings on
HRCT, and increased in those with borderline parenchymal
changes, but was even higher in subjects with diffuse
fibrosis (asbestosis) in our previous study (3.2  0.4 ppb).16
It seems, thus, that alveolar NO is related to the degree of
pulmonary fibrosis rather than to asbestos exposure per se.
As we excluded subjects with obstructive lung function or
any emphysema detectable on HRCT, we believe that the
increased alveolar NO concentration in asbestos-exposed
subjects with borderline parenchymal changes is related
to asbestos induced process and not to other pulmonary
diseases. This is also supported by the ability of asbestos to
induce the expression of inducible NO synthase (iNOS) in
human pneumocytes in vitro.21estos-exposed subjects with normal (N, n Z 35) or borderline
comparison group (n Z 41)(mean  SEM).
Table 3 Exhaled NO concentrations (ppb) at different flow rates, alveolar and bronchial NO parameters and inflammatory
markers.
Asbestos-exposed subjects Unexposed comparison
group n Z 41Normal parenchymal
findings n Z 35
Borderline parenchymal
changes n Z 31
FENO0.05 (ppb) 17.3  1.2a 20.0  2.0 22.3  1.6
FENO0.1 (ppb) 9.8  0.7a 11.2  1.0 12.2  0.9
FENO0.2 (ppb) 5.9  0.4 6.9  0.6 7.1  0.5
FENO0.3 (ppb) 4.7  0.3 5.7  0.5 5.6  0.3
CANO (ppb) 2.2  0.2 3.0  0.2b 2.3  0.1
J’awNO (nl/s) 0.7  0.1a 0.8  0.1 1.0  0.1
EBC 8-isoprostane (pg/ml) 8.3  0.6 9.5  0.8a 7.3  0.6
EBC LTB4 (pg/ml) 11.4  0.9c 12.3  1.1c 3.3  0.8
S-IL-6 (pg/ml) 3.5  0.3 4.5  0.6a 3.1  0.4
S-MPO (pg/ml) 141  7 158  6a 140  5
FENO0.05, Exhaled NO concentration at exhalation flow rate of 50 ml/s.
CANO, alveolar NO concentration.
J’awNO, bronchial NO flux.
EBC, exhaled breath condensate.
a p < 0.05 as compared with the unexposed comparison group.
b p < 0.01 as compared with the unexposed comparison group.
c p < 0.001 as compared with the unexposed comparison group.
Pulmonary inflammation and asbestos exposure 1047Alveolar NO has been found to correlate with impaired
lung function in diseases like idiopathic pulmonary fibrosis
and COPD.10,11 However, there was no significant correla-
tion in the present study between alveolar NO and lung
function. If we had included also subjects with severe
pulmonary fibrosis (i.e. asbestosis) and thereby widened
the range in disease severity a correlation might have been
found.
Bronchial NO flux was decreased in asbestos-exposed
subjects with normal parenchymal findings, and to a lesser
extent also in those with borderline parenchymal changes
on HRCT. This might be related to the higher proportion of
ex-smokers in the asbestos-exposed subjects, as decreased
bronchial NO flux is reported in healthy ex-smokers asFigure 3 Levels of 8-isoprostane and leukotriene B4 (LTB4) in exha
normal (N, n Z 35) or borderline (BL, n Z 31) parenchymal
(n Z 41)(mean  SEM).compared with never-smokers.22 The decreased bronchial
NO flux in asbestos-exposed subjects with normal paren-
chymal findings was reflected also as decreased exhaled NO
concentrations at flow rates of 50 and 100 ml/s, in which
the relative proportion of NO from bronchial sources is
bigger than in the higher flow rates. In contrast, the
increase in peripheral NO output in subjects with borderline
parenchymal changes was not reflected as increased NO
concentrations at any single flow rate. This demonstrates
the superiority of the multiple flow rate method in assess-
ing the changes in peripheral NO output.
Condensate levels of LTB4 were increased in both groups
with asbestos exposure, but 8-isoprostane levels were
increased only in subjects with borderline parenchymalled breath condensate (EBC) in asbestos-exposed subjects with
findings on HRCT, and in the unexposed comparison group
Figure 4 Alveolar NO concentration correlated positively with exhaled breath condensate (EBC) levels of 8-isoprostane and
negatively with EBC levels of leukotriene B4 (LTB4) in the asbestos-exposed subjects (n Z 66).
1048 L. Lehtima¨ki et al.changes. LTB4 is a potent chemotactic factor for neutro-
phils,14 and occupational asbestos exposure has been shown
to provoke LTB4 secretion in alveolar macrophages in
vivo.23 8-isoprostane is produced by lipid peroxidation and
can be used as a marker of oxidative injury in many
diseases.15 These findings together with our present results
suggest that LTB4 level in EBC reflects the inflammatory
response to asbestos, while EBC level of 8-isoprostane is
related to the degree of oxidative stress, tissue damage and
fibrosis. As also alveolar NO concentration was increased
only in subjects with borderline changes on HRCT, it can be
understood that 8-isoprostane correlated positively with
alveolar NO. The negative correlation between condensate
levels of LTB4 and alveolar NO concentration further
supports the hypothesis that LTB4 is related to inflamma-
tory state while 8-isoprostane and alveolar NO reflect tissue
damage and fibrosis.
Asbestos exposure stimulates alveolar macrophages to
produce IL-6, which is involved in recruitment of inflam-
matory cells and in fibroblast proliferation.1 Increased
serum levels of IL-6 have previously been shown in
asbestos-exposed subjects with or without pulmonary
fibrosis.16,24 MPO is a major constituent of neutrophils and
it generates hypochlorus acid and reactive nitrogen
species. Asbestos exposure induces pulmonary MPO
production that plays a role in the tissue damage and
cancer risk.25,26 We found increased serum levels of IL-6
and MPO only in those asbestos-exposed subjects who had
borderline parenchymal changes on HRCT. This suggests
either that these subjects had more pronounced inflam-
matory response to asbestos than those with normal
parenchymal findings, or that serum levels of IL-6 and MPO
are related to the development of minor parenchymal
changes on HRCT. It might be that individual differences in
immune responses to asbestos determine the production of
inflammatory mediators, and thereby the susceptibility to
develop asbestos related diseases.
Interestingly, there was no correlation between the
degree of asbestos exposure and the extent of pleural and
parenchymal changes seen on HRCT. This might also be
related to individual differences in immune responses to
asbestos, which determines the susceptibility to develop
fibrotic changes after asbestos exposure. However, the
assessment of asbestos exposure was based on retrospectiveinterview and this may cause some inaccuracy in the expo-
sure indices.
Minor fibrotic changes on HRCT have been found even in
asbestos-exposed subjects with normal lung function and
chest X-ray.3,27 When comparing HRCT findings with histo-
logical signs of asbestosis, it has been shown that paren-
chymal changes on HRCT should be bilateral or multifocal
to suggest diffuse fibrosis. Unilateral or focal changes on
HRCT are not considered sufficient for the diagnosis of
diffuse fibrosis (asbestosis), although histological evidence
of asbestosis like changes have been found in some cases
with normal or nearly normal HRCT.7 The borderline
parenchymal changes on HRCT might be an early sign of
future diffuse fibrosis. If this is the case, the non-invasive
markers of inflammation and oxidative stress used in the
current study might be useful in predicting the individual
risk of disease progression.
In conclusion, borderline parenchymal changes on HRCT
in asbestos-exposed subjects are associated with pulmo-
nary inflammation. The profile of inflammatory markers in
asbestos-exposed subjects with borderline parenchymal
changes resembles that found in patients with frank
asbestosis in our previous study,16 while subjects with
normal parenchymal finding but similar asbestos exposure
have nearly normal levels of inflammatory markers. Such
borderline parenchymal changes are therefore likely a mild
or early form of the same pathological process that leads to
asbestosis. A follow-up study is needed to assess if the
markers of inflammation could be used to predict the risk of
developing diffuse pulmonary fibrosis and asbestosis among
subjects with borderline parenchymal changes.Acknowledgements
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